Miyako Capital

Miyako Capital is the venture capital that manages Kyoto University 2nd Venture Fund (KUVF). The company was founded in 2013 and based in Kyoto & Tokyo, Japan. Investment fields are: 1) Life Science, Biotechnology: Drug creation, regenerative medicine, medical beauty equipment, medical services. 2) Agri-Food: Industrialization, agricultural and fishery products growth-promoting technology, specified health food, health food. 3) Environment, Energy: Alternative energy, and related technologies. 4) IT, Electronics: Web, mobile related devices and application, telecommunication technology, security, consumer and business oriented application, mechatronic, robot. 5) New services utilizing state-of-art technology. Investment stages: Primary investment stages are initial-growth stages of seed and early. However, we aim at all growth stages and make investment in post-IPO portfolio companies as well as public companies that are related with Kyoto University.

Tan Hazama

Venture Partner

Rui He

Principal

Hiroaki Okahashi

Co-Partner and Co-Founder

Junko Sugaya

Director and Partner

Yamaguchi, Satoshi

Co-Partner and Co-Founder

34 past transactions

SocialGood App

Series A in 2022
SocialGood, Inc.’s mission is to build the world’s largest global platform and to provide financial freedom to all people worldwide. The more they shop through the SocialGood App, the more assets users earn. There are over 2.3 million users from more than 200 countries and territories worldwide. The app has API-partnered with over 20,000 major shopping websites, and users can earn SocialGood (SG) cryptocurrency in proportion to how much they spend at these stores. SocialGood, Inc. has registered 68 patents in Japan, including their patented Crypto Back system.

VLP Therapeutics

Series A in 2021
VLP Therapeutics, LLC (VLP) was established in 2012 by seasoned biopharmaceutical veterans with mission to develop innovative medical treatment which transforms traditional vaccine and targeted antibody therapies to address global unmet medical needs. Its vision is to combat the 21st century global public health problems through revolutionary next generation i-αVLP (inserted alpha VLP) Technology. The company is headquartered in Gaithersburg, Maryland

VividQ

Seed Round in 2021
VividQ is bringing about a revolution in digital display and creating the human-machine interface for the next generation of consumer devices. VividQ's computational display technology is creating a future where 3D holographic images are cast into our everyday environment, removing the screens that separate our real and virtual experiences. The company partners with leading original electronics manufacturers (OEMs) to integrate its advanced software and hardware solutions into augmented reality (AR), virtual reality (VR), automotive head-up displays, and other consumer electronics. Founded in 2017, the company is based in Cambridge, U.K., with partners and teams in the U.S. and Japan.

Startbahn

Series B in 2021
Startbahn aims to realize a richer society by providing the technology needed by artists and people involved with art all over the world. We are developing Startbahn Cert., a service that issues blockchain certificates for artworks, and promoting the development of Startrail, a blockchain infrastructure that is the basis for Startbahn Cert. We also run joint projects with other companies.

VLP Therapeutics

Series A in 2021
VLP Therapeutics, LLC (VLP) was established in 2012 by seasoned biopharmaceutical veterans with mission to develop innovative medical treatment which transforms traditional vaccine and targeted antibody therapies to address global unmet medical needs. Its vision is to combat the 21st century global public health problems through revolutionary next generation i-αVLP (inserted alpha VLP) Technology. The company is headquartered in Gaithersburg, Maryland

HACARUS

Series B in 2020
HACARUS is a provider of Explainable Lightweight AI Tools, backed by Miyako Capital (Kyoto University) among others. Its solutions are used in the Medical and Manufacturing fields to enable humans to make better, faster and more reliable decisions, based on AI driven insights. Hacarus' proprietary AI engine is built using Sparse Modeling, an AI method that understands data like a human would - by its unique key features and is far more resource, time and energy efficient when compared to Deep Learning.

Floadia

Series C in 2020
Floadia Corporation is an energetic start up, focused on providing embedded non-volatile memory IP solutions.The engineering team came from Renesas who has been developing embedded FLASH technology for over 20 years, including the inventor of "Source Side Injection" for Split Gate FLASH, which is the fundamental technology for commonly used FLASH architecture today.

CellAxia

Series B in 2020
CellAxia is a biotechnology startup that creates medications for cell treatment. Drug discovery bio-venture aiming at the practical application of advanced research such as cell therapy. It serves clients operating in the healthcare sector.

BizteX

Series C in 2020
BizteX is a software robotics company that uses cloud Robotic Process Automation to automate routine operations. The company develops SaaS services centered on cloud RPA and expand it globally to contribute to the creation of creativity for many people. The company's service called, BizteX cobit, is a digital robot that performs a one-click substitute for humans by instructing routine work. BizteX was founded in July 2015 and is headquartered in Tokyo, Japan.

Liberaware

Venture Round in 2020
Liberaware specializes in non-GPS small drones for industrial use that offer IoT and AI-driven solutions, and video editing services.

GORYO Chemical

Venture Round in 2019
GORYO Chemical specializes in sales of functional dyes Contract synthesis of functional dyes and development of diagnostic agents.

Integral Geometry Science

Venture Round in 2019
IGS investigates theories and methods for visualizing object internal structures. The company is developing, manufacturing, and selling the world's highest performance measurement system based on Dr. Kimura's and others' multi-path scattered field theory, which is known as an unsolved problem in the history of applied mathematics.

Atomis

Series A in 2019
Atomis provides global solutions for precisely controlling gases. Its core technology, porous coordination polymers (PCPs; also known as metal-organic frameworks (MOFs)), is based on research developed by Distinguished Professor Susumu Kitagawa at the Institute for Advanced Study at Kyoto University. It aims not only to provide solutions such as the optimization for manufacturing processes of PCPs but to also develop applications that provide innovative value using these materials. It was founded by Masakazu Higuchi in 2015 and is headquartered in Kyoto, Japan.

Integral Geometry Science

Venture Round in 2019
IGS investigates theories and methods for visualizing object internal structures. The company is developing, manufacturing, and selling the world's highest performance measurement system based on Dr. Kimura's and others' multi-path scattered field theory, which is known as an unsolved problem in the history of applied mathematics.

StemRIM

Venture Round in 2018
Stem Rim is a biotechnology company aiming to develop “regenerative medicine”.We are developing drugs based on a new mechanism of action that mobilizes stem cells present in the living body to the injured or diseased tissue without removing them out of the body and induces functional tissue regeneration.

HACARUS

Series A in 2018
HACARUS is a provider of Explainable Lightweight AI Tools, backed by Miyako Capital (Kyoto University) among others. Its solutions are used in the Medical and Manufacturing fields to enable humans to make better, faster and more reliable decisions, based on AI driven insights. Hacarus' proprietary AI engine is built using Sparse Modeling, an AI method that understands data like a human would - by its unique key features and is far more resource, time and energy efficient when compared to Deep Learning.

ARTham Therapeutics

Series A in 2018
ARTham Therapeutics creates value by developing medicines that are disease-modifying and improve patient health. They operate a virtual research and development model that seeks innovation through academic and business partners.

Trigence

Series C in 2018
Trigence Semiconductor, Inc. operates as an audio IC design and solution provider. The company offers digital audio products, such as Digital Speaker Module that include speakers, enclosures, connectors, FPCs, audio DSPs, and interfaces to simplify development for PC, tablet, and smartphone required audio functionality; and digital speaker drivers, USBs, and evaluation boards for the consumer and IT markets. It provides products for applications in computer and laptop, headsets, sound-bar, and Bluetooth speaker. The company offers its products through distributors. Trigence Semiconductor, Inc. was founded in 2006 and is based in Tokyo, Japan with offices in Japan, the United States, Hong Kong, and Taiwan.

Megakaryon

Series C in 2017
Megakaryon is a medical research company that develops and sells blood products.

StemRIM

Venture Round in 2017
Stem Rim is a biotechnology company aiming to develop “regenerative medicine”.We are developing drugs based on a new mechanism of action that mobilizes stem cells present in the living body to the injured or diseased tissue without removing them out of the body and induces functional tissue regeneration.

Institution for a Global Society

Corporate Round in 2017
Institution for a Global Society provides education institutions and businesses with innovative, seamless, and bias-less assessment solutions. The company's solutions include GROW Academy, DxGROW, Ai GROW, and GROW360. The company uses appropriate technology ethically to create a society where everyone can sustainably learn and develop over the course of a lifetime.

REGiMMUNE

Venture Round in 2017
REGiMMUNE Corporation is a private biopharmaceutical company developing innovative solutions for treating immune disorders caused by nonspecific and/or excessive immune reactions. REGiMMUNE uses its proprietary technology platform, reVax (reverse vaccination), to target immune tolerance against specific disease-causing antigens through induction of regulatory T cells (Treg). This technology has potential applications in a number of immune system disorders and diseases including Graft versus Host Disease (GvHD), type 1 diabetes mellitus (T1DM), rheumatoid arthritis (RA), multiple sclerosis (MS) and systemic lupus erythematosus (SLE). Currently, the company has one clinical-stage compound in a Phase I/II trial in the United States (RGI-2001) as a treatment for GvHD associated with hematopoietic stem cell transplantation and has a second product in preclinical development (RGI-3001) as a new treatment for T1DM. In addition, it has a number of well-differentiated compounds in its research-stage pipeline. In healthy individuals, the normal immune system works to protect humans from disease-causing viruses, bacterium, and cancers; or foreign antigens such as peanuts, wheat and tree pollens. Conventional immunosuppressants have several significant side effects associated with long-term administration including risk of infection, toxicity and relapse. Products developed with ReVax technology are expected to reduce or eliminate such side effects as well as reduce long-term treatment.

Drivemode

Series A in 2017
Drivemode was founded in 2014 by entrepreneurs from Zipcar and Tesla Motors who set out to fundamentally change the way you use technology in the car. Our goal is to create products that makes you immediately wonder how you ever lived without it. Drivemode enables smarter, safer, connected driving in any vehicle through your device. Voice-to-text messaging, music player overlay on navigation, and more. The Drivemode Android App was released at the end of July 2015, and has quickly become the largest connected car platform with more than 1 million downloads from 180+ countries and hundreds of years of comprehensive driving data to date. This rapid growth, ability to engage users, and deep knowledge of driver behavior has attracted various key players in the connected car ecosystem to further bolster our position as an emerging platform. Drivemode is currently working with various connected car players and automakers as seen on various media outlets.

FLOSFIA

Venture Round in 2017
FLOSFIA is a spin-off from a research of Kyoto University, specializing in film-formation by mist chemical vapor deposition (CVD). Making use of physical properties of gallium oxide (Ga2O3), FLOSFIA has devoted to development of low-loss power devices.

HACARUS

Seed Round in 2016
HACARUS is a provider of Explainable Lightweight AI Tools, backed by Miyako Capital (Kyoto University) among others. Its solutions are used in the Medical and Manufacturing fields to enable humans to make better, faster and more reliable decisions, based on AI driven insights. Hacarus' proprietary AI engine is built using Sparse Modeling, an AI method that understands data like a human would - by its unique key features and is far more resource, time and energy efficient when compared to Deep Learning.
KDDD develop an innovative agent effective for various INCURABLE or INTRACTABLE eye diseases, especially CRAO, Retinal Pigmentosa, AMD and Glaucoma.

Integral Geometry Science

Venture Round in 2016
IGS investigates theories and methods for visualizing object internal structures. The company is developing, manufacturing, and selling the world's highest performance measurement system based on Dr. Kimura's and others' multi-path scattered field theory, which is known as an unsolved problem in the history of applied mathematics.

AFI Technology

Series A in 2016
AFI Technology manufactures and sells products that use this technology, and responds to a wide range of requests, such as rapid microbiological testing.

Farmship

Venture Round in 2015
Farmship is an AgriTech company that develops a sustainable Agri system. Farmship is an Agritech company that supports future agriculture through technology, distribution, human resources, and business development.

Megakaryon

Series B in 2015
Megakaryon is a medical research company that develops and sells blood products.

Helpfeel

Series A in 2014
Nota is the company behind Gyazo, the highly popular and rapidly growing cloud-based screen capture and sharing application. Gyazo allows users to instantly share a full and partial screenshot with a custom URL from a PC/Mac desktop app. Gyazo has grown rapidly to a worldwide user base of more than 8 million through viral user acquisition. The company’s aim is to become a truly global company yet with uniquely Japanese roots. The company was established in 2007 and is based in Menlo Park, California with offices in Kyoto and Tokyo, Japan.

iHeart

Series A in 2014
iHeart Japan Corporation is developing regenerative medicinal products for severe heart failure, using iPSC technologies. Its base technologies were invented by scientists of Kyoto University.

MONEY DESIGN

Seed Round in 2014
Moneydesign is fin-tech company that offers automated investment management and advisory services.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.